Hypertriglyceridemia in antiretroviral therapy

MedGenMed Medscape General Medicine

Volumn 7, Issue 3, 2005, Pages

  Imarhiagbe, Frank Aiwansoba ^a,b   Kubeyinje, Emmanuel Pandy ^a  

^a UNIVERSITY OF BENIN   (Nigeria)

^b FEDERAL MEDICAL CENTER   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; STAVUDINE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; COST OF ILLNESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LYMPHOCYTE COUNT; MALE; NIGERIA; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; WESTERN BLOTTING;

EID: 33750358634     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: 10.1186/1758-2652-7-3-65     Document Type: Article

References (12)

1. Fauci AS, Lane HC. Human immunodeficiency virus (HIV) disease: AIDS and related disorders - disease of the endocrine and metabolic disorders. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson DL, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001.
2. Qaqish RB, Fisher E, Rublein J, Wohl DA. HIV-associated lipodystrophy syndrome. Pharmacotherapy. 2000;20:13-22 Abstract
3. van der Valk M, Reiss P. Lipids profiles associated with antiretroviral drug choices. Curr Opin Infect Dis. 2003;16:19-23. Abstract
4. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004; 189:1056-1074.
5. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383-1389. Abstract
6. Friss-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193. Abstract
7. Domingo P, Sambeat M.A, Perez A, Ordonez J, Rodriguez J, Vazquez G. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Antivir Ther. 2003;8:223-231. Abstract
8. Greenberger NJ, Toskes PP. Biochemistry and physiology of pancreatic exocrine secretion. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson DL, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001.
9. Neuman T, Woiwoid T, Neuman A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: part 1. Differences due to the acquisition of HIV-infection. Eur J Med Res. 2003;8:229-235. Abstract
10. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO. Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS. 2003;17:189-194. Abstract
11. Mikhail N. Insulin resistance in HIV-related lipodystrophy. Curr Hypertens Rep. 2003;5:117-121. Abstract
12. Calza L, Manfredi R, Chiudo F. Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART. Infection. 2002;30:26-31. Abstract